Monopar Therapeutics (MNPR) Reiterated at Overweight by Cantor Fitzgerald: On Track
Tweet Send to a Friend
Cantor Fitzgerald analyst Kirsten Kluska reiterated an Overweight rating and $109.00 price target on Monopar Therapeutics (NASDAQ: MNPR).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
